Featured Article
AC Immune has signed a major deal with Japanese big pharma Takeda with a view to getting its amyloid-beta Alzheimer's vaccine to the market.
Precision Oncology Today
Magazine
Beginning a New Era of Precision Alzheimer’s Therapeutics
Alzheimer’s is a disease associated with aging and impacts almost seven million people in the U.S. over the age of 65, with women and Black or Hispanic populations disproportionately affected by the condition. Finding an effective treatment for Alzheimer’s disease has proved to be a long and difficult quest.
5 Startups With Proteomics Potential Attracting Investor Cash
Investor appetite is growing for startups that can make proteomics faster, cheaper, and more informative for use in precision medicine. Here are five proteomics...
Trending on Inside Precision Medicine
Intense Ultrasound Releases Cancer Biomarkers, Allows for Earlier Cancer Detection
A team of researchers from the University of Alberta, Canada, has demonstrated that applying intense ultrasound--at levels much higher than used for imagining--can cause the release of biomarkers from cells, allowing for earlier detection of cancer via liquid biopsy.
Genetic Variant Linked to Cardiovascular Disease and Death in Black Americans
A specific variant, present in three to four percent of Blacks in the U.S., increases the risk for both heart failure and death and contributes to significant decreases in longevity.
Takeda Signs Deal Worth $2.2 Billion with AC Immune for Alzheimer’s Vaccine
AC Immune has signed a major deal with Japanese big pharma Takeda with a view to getting its amyloid-beta Alzheimer's vaccine to the market.
